Related Experiment Video
Updated: Oct 21, 2025

Injections of Lipopolysaccharide into Mice to Mimic Entrance of Microbial-derived Products After Intestinal Barrier Breach
Published on: May 2, 2018
Elevated colonic microbiota-associated paucimannosidic and truncated N-glycans in pediatric ulcerative colitis
Henghui Li1, Xu Zhang1, Rui Chen2
1Ottawa Institute of Systems Biology and Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, ON K1H 8M5, Canada.
Insights
Pediatric ulcerative colitis (UC) microbiota show higher levels of atypical N-glycans. These small glycans, including truncated forms, may serve as novel biomarkers for diagnosing pediatric UC.
Area of Science:
- Gastroenterology
- Microbiology
- Glycomics
Background:
- Pediatric ulcerative colitis (UC) is a severe inflammatory bowel disease with unclear pathogenesis.
- Gut microbiota dysbiosis is implicated in UC development, but host-microbiome interactions remain poorly understood.
- Current pediatric UC diagnosis relies on invasive procedures.
Purpose of the Study:
- To investigate N-glycans associated with intestinal microbiota in pediatric UC.
- To identify potential glycan biomarkers for pediatric UC diagnosis.
Main Methods:
- Collected intestinal mucosal-luminal interface microbiota samples from treatment-naïve pediatric UC patients and controls.
- Utilized two mass spectrometry-based glycomic approaches for N-glycan analysis.
Main Results:
- Observed abundant small N-glycans associated with microbiota.
- Found significantly higher levels of atypical N-glycans in pediatric UC microbiota compared to controls.
- Identified four specific N-glycans that effectively distinguished UC patients from controls (AUC ≥ 0.9).
Conclusions:
- Aberrant glycan metabolism by gut microbiota may contribute to pediatric UC pathogenesis.
- Intestinal N-glycans, particularly small and truncated forms, show promise as novel biomarkers for pediatric UC.
- Findings offer insights into host-microbiome interactions and potential non-invasive diagnostic tools.
Abstract:
Pediatric ulcerative colitis (UC) is a distinct type of inflammatory bowel disease with severe disease activity and rapid progression, which can lead to detrimental life-long consequences. The pathogenesis of pediatric UC remains unclear, although dysbiosis of the gut microbiota has been considered an important factor. In this study, we collected intestinal mucosal-luminal interface microbiota samples from a cohort of treatment-naïve pediatric UC or control patients and used two different mass spectrometry-based glycomic approaches to examine the N-glycans that were associated with the microbiota. We observed abundant small N-glycans that were associated with the microbiota and found that the pediatric UC microbiota samples contained significantly higher levels of these atypical N-glycans compared to those of controls. Four paucimannosidic or other truncated N-glycans were identified to successfully segregate UC from control patients with an area under the ROC curve of ≥0.9. This study indicates that the aberrant metabolism of glycans in the intestinal by gut microbiota may be involved in the pathogenesis of UC and intestinal N-glycans, including small glycans, can act as novel biomarker candidates for pediatric UC. SIGNIFICANCE: There is no cure for pediatric ulcerative colitis (UC) due to its unclear pathogenesis and the diagnosis of UC in children still largely depends on invasive colonoscopic examination. Recent evidence suggests that the dysbiosis of intestinal microbiota is associated with the onset and development of UC, however how the microbiota interact with the host remains unclear. This study used two different mass spectrometry-based glycomic approaches to quantitatively examine N-glycans that are associated with colonic mucosal-luminal interface microbiota of pediatric UC or control patients. To the best of our knowledge, this is the first comprehensive glycomic study of intestinal microbiota samples in UC, which demonstrated that intestinal microbiota was associated with abundant atypical small N-glycans with elevated levels in UC than controls. This study also identified four intestinal paucimannosidic or other truncated N-glycans as promising biomarker candidates for pediatric UC. These findings shed light on the mechanism study of host-microbiome interactions in UC and indicate that atypical glycans present in the gut can be a source for UC biomarker discovery.
Related Concept Videos
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Drugs for Treatment of Ulcerative Colitis in IBD
Renewal of Intestinal Stem Cells
Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...

